Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Non-Current Debt (2018 - 2025)

Historic Non-Current Debt for Rockwell Medical (RMTI) over the last 10 years, with Q3 2025 value amounting to $8.7 million.

  • Rockwell Medical's Non-Current Debt rose 422.28% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year increase of 422.28%. This contributed to the annual value of $8.5 million for FY2024, which is 215.84% up from last year.
  • Rockwell Medical's Non-Current Debt amounted to $8.7 million in Q3 2025, which was up 422.28% from $8.6 million recorded in Q2 2025.
  • Rockwell Medical's Non-Current Debt's 5-year high stood at $21.0 million during Q1 2021, with a 5-year trough of $3.3 million in Q3 2023.
  • In the last 5 years, Rockwell Medical's Non-Current Debt had a median value of $8.5 million in 2024 and averaged $9.4 million.
  • Per our database at Business Quant, Rockwell Medical's Non-Current Debt tumbled by 6283.2% in 2023 and then skyrocketed by 15166.62% in 2024.
  • Over the past 5 years, Rockwell Medical's Non-Current Debt (Quarter) stood at $13.2 million in 2021, then tumbled by 42.7% to $7.6 million in 2022, then grew by 9.77% to $8.3 million in 2023, then increased by 2.16% to $8.5 million in 2024, then rose by 3.13% to $8.7 million in 2025.
  • Its Non-Current Debt stands at $8.7 million for Q3 2025, versus $8.6 million for Q2 2025 and $8.6 million for Q1 2025.